Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

Norethindrone

Unique Identifier:LAT002B05
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:C20H26O2
Molecular Weight:273.221 g/mol
X log p:1.448  (online calculus)
Lipinksi Failures0
TPSA17.07
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:2
Rotatable Bond Count:0
Canonical Smiles:CC12CCC3C(CCC4=CC(=O)CCC34)C1CCC2(O)C#C
Generic_name:Norgestrel
Chemical_iupac_name:13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyc
lopenta[a]phenanthren-3-one
Drug_type:Approved Drug
Kegg_compound_id:C08153
Drugbank_id:APRD00106
Melting_point:206oC
Logp:3.251
Cas_registry_number:6533-00-2
Drug_category:Contraceptives; ATC:G03AC03
Indication:Used as an oral contraceptive to prevent pregnancy
Pharmacology:Norgestrel is used as a female contraceptive. Norgestrel is a progestin or a
synthetic form of the naturally occurring female sex hormone, progesterone. In a
woman-s normal menstrual cycle, an egg matures and is released from the ovaries
(ovulation). The ovary then produces progesterone, preventing the release of further
eggs and priming the lining of the womb for a possible pregnancy. If pregnancy
occurs, progesterone levels in the body remain high, maintaining the womb lining. If
pregnancy does not occur, progesterone levels in the body fall, resulting in a
menstrual period. Norgestrel tricks the body processes into thinking that ovulation
has already occurred, by maintaining high levels of the synthetic progesterone. This
prevents the release of eggs from the ovaries.
Mechanism_of_action:Norgestrel binds to the progesterone and estrogen receptors. Target cells include
the female reproductive tract, the mammary gland, the hypothalamus, and the
pituitary. Once bound to the receptor, progestins like Norgestrel will slow the
frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus
and blunt the pre-ovulatory LH (luteinizing hormone) surge.
Organisms_affected:Humans and other mammals

Found: 5 nonactive as graph: single | with analogs 2 3 4 5 Next >> 
Species: 4932
Condition: pdr18h
Replicates: 2
Raw OD Value: r im 0.6050±0.0234759
Normalized OD Score: sc h 0.9576±0.0395151
Z-Score: -1.0155±1.03354
p-Value: 0.428304
Z-Factor: -3.84026
Fitness Defect: 0.8479
Bioactivity Statement: Nonactive
Experimental Conditions
Library:LATCA
Plate Number and Position:2|B5
Drug Concentration:50.00 nM
OD Absorbance:600 nm
Robot Temperature:25.10 Celcius
Date:2007-03-08 YYYY-MM-DD
Plate CH Control (+):0.03955±0.00248
Plate DMSO Control (-):0.647475±0.01609
Plate Z-Factor:0.8987
png
ps
pdf

DBLink | Rows returned: 77<< Back 11 12 13 Next >> 
11865446 (8S,9S,10S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclope
nta[a]phenanthren-3-one
11869446 (8R,9S,10S,13R,14R,17S)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclo
penta[a]phenanthren-3-one
11869447 (8R,9S,10R,13R,14R,17S)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclo
penta[a]phenanthren-3-one
11869448 (8S,9S,10S,13R,14R,17S)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclo
penta[a]phenanthren-3-one
11869449 (8S,9S,10R,13R,14R,17S)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclo
penta[a]phenanthren-3-one
11885588 (8R,9S,10R,13S,14R,17S)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclo
penta[a]phenanthren-3-one

internal high similarity DBLink | Rows returned: 72 Next >> 
NRB 03706 1.0000
Prest109 1.0000
Prest639 1.0000
Prest646 1.0000
SPE01500437 1.0000
SPE01500441 1.0000

nonactive | Cluster 2558 | Additional Members: 8 | Rows returned: 5
Prest533 0.373134328358209
Prest109 0.367647058823529
SPE01500441 0.367647058823529
Prest646 0
SPE01500437 0

Service provided by the Mike Tyers Laboratory